Caris Life Sciences, Inc. (CAI) AI Stock Analysis

• Market Cap: $9.23B
• Dividend Yield: N/A
• Average Volume (3M): 676.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,769
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 281,224,120
• 10 Day Avg. Volume: 898,944
• 30 Day Avg. Volume: 676,550
• PEG Ratio: -0.52
• Price to Book (P/B): -2.85
• Price to Sales (P/S): 17.30
• P/FCF Ratio: -28.11
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 23.84
• Enterprise Value/Gross Profit: 42.21
• Enterprise Value/Ebitda: -55.90
• 1Y Price Target: $38.25
• Price Target Upside: 16.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 51 Neutral
• Price Target: $35.00 ▲(6.67% Upside)

Caris Life Sciences, Inc. has a moderate overall stock score driven by positive technical indicators, despite significant financial challenges. The lack of valuation metrics and earnings call data limits a comprehensive assessment.

Positive Factors

Business Model Strength

Caris's focus on precision medicine and molecular intelligence positions it well in the growing field of personalized healthcare, offering durable demand for its services.

Market Position

Caris's comprehensive tumor profiling service strengthens its market position by providing critical insights for cancer treatment, enhancing its competitive edge in biotechnology.

Revenue Streams

Diverse revenue streams from tests, subscriptions, and partnerships provide stability and growth potential, supporting long-term financial health.

Negative Factors

Financial Leverage

High leverage and negative equity suggest financial instability, potentially limiting the company's ability to invest in growth and navigate economic downturns.

Profitability Challenges

Ongoing profitability challenges with negative margins indicate operational inefficiencies, which could hinder long-term sustainability and growth.

Cash Flow Issues

Negative cash flows highlight liquidity issues, potentially restricting operational flexibility and the ability to fund strategic initiatives.

Caris Life Sciences, Inc. Business Overview & Revenue Model

Company Description

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

How the Company Makes Money

Caris Life Sciences generates revenue through the provision of its molecular profiling services to healthcare providers, hospitals, and oncologists. The company charges fees for its tests, which analyze tumor samples to identify genetic alterations and biomarkers that can inform treatment decisions. Key revenue streams include payments for individual tests, subscription models for ongoing services, and partnerships with pharmaceutical companies for drug development and clinical trials. Additionally, Caris may benefit from collaborations with academic institutions and research organizations, which can lead to increased usage of its profiling services in research and clinical practice.

Caris Life Sciences, Inc. Financial Statement Overview

Summary

Caris Life Sciences, Inc. faces significant financial challenges with declining profitability, high leverage, and negative cash flows, indicating financial instability and risk.

Income Statement

Caris Life Sciences, Inc. has experienced a decline in profitability over recent years, with negative net profit margins and EBIT margins indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in 2020. The company has struggled to maintain positive margins, reflecting difficulties in managing costs relative to revenue.

Balance Sheet

The balance sheet shows significant financial leverage, with a negative stockholders' equity and a high debt-to-equity ratio in earlier years. This indicates potential financial instability and risk. The return on equity has been positive but low, suggesting limited returns for shareholders given the high leverage.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows in recent years, indicating liquidity challenges. The free cash flow to net income ratio is positive, suggesting some efficiency in converting income to cash, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	302.31M	412.26M	306.13M	258.49M	294.01M	416.54M
Gross Profit	170.75M	178.78M	89.31M	80.02M	184.16M	200.51M
EBITDA	-128.93M	-182.95M	-260.80M	-245.89M	201.75M	228.29M
Net Income	-174.37M	-281.89M	-341.42M	-320.83M	27.73M	31.01M
Balance Sheet
Total Assets	955.06M	343.73M	412.90M	717.42M	2.61B	2.90B
Cash, Cash Equivalents and Short-Term Investments	721.18M	66.15M	121.59M	409.62M	132.54M	46.46M
Total Debt	418.98M	424.26M	217.27M	270.87M	1.75B	2.10B
Total Liabilities	502.15M	2.84B	2.56B	2.42B	1.91B	2.21B
Stockholders Equity	452.90M	-2.50B	-2.14B	-1.70B	702.24M	693.24M
Cash Flow
Free Cash Flow	-28.13M	-253.64M	-298.42M	-327.96M	57.57M	-65.14M
Operating Cash Flow	-24.05M	-245.20M	-276.10M	-285.71M	277.02M	254.00M
Investing Cash Flow	-4.08M	52.93M	214.77M	-282.99M	-33.97M	-271.87M
Financing Cash Flow	682.69M	200.29M	10.13M	10.45M	-249.88M	-108.48M

Caris Life Sciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	54 Neutral	$10.10M	―	-81.33%	―	-62.68%	23.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAI	51 Neutral	$9.23B	―	―	―	―	―
SNSE	40 Underperform	$11.99M	―	-67.47%	―	―	9.63%
MSPR	38 Underperform	$1.50M	―	-2151.29%	―	76.98%	-52.89%
INAB	34 Underperform	$10.67M	―	-165.56%	―	―	58.67%